



Belgian Cancer Registry

CANCER FACT SHEET 2023

HEAD & NECK CANCER





ICD-10 C00-C14; C30-C32






Key facts

- 6th most common cancer in males
- 9th most common cancer in females
- 2,672 new diagnoses in 2023
- 679 deaths due to H&N cancer in 2021
- 5-year net survival of **58.4%**

Lifetime risk (0-84 years)






- Median age at diagnosis for H&N cancer is **67 years**
- Known risk factors include smoking, alcohol consumption and human papilloma virus (HPV) infection
- There is a **higher risk** of H&N cancer diagnosis **closer to the French border**
- **More than half** of H&N cancers are located **in the oral cavity or oropharynx**


Incidence by sub-location, N(%)	Males		Females	
Lip	33	(1.7%)	22	(2.8%)
Oral cavity	421	(22.2%)	290	(37.2%)
Oropharynx	560	(29.6%)	189	(24.3%)
Nasopharynx	60	(3.2%)	20	(2.6%)
Hypopharynx	221	(11.7%)	40	(5.1%)
Larynx	411	(21.7%)	99	(12.7%)
Nasal cavity and paranasal sinuses	104	(5.5%)	44	(5.7%)
Salivary glands	76	(4.0%)	71	(9.1%)
Other and ill-defined sites	7	(0.4%)	4	(0.5%)



Stage distribution by main sublocation



HPV status in oropharyngeal cancer




Squamous cell carcinomas of the oropharynx

- Stage distribution is dependent on **sub-location**
- **More than one in three oropharyngeal cancers** is related to **HPV infection**
- Prognosis is dependent on HPV status, available on page 5
- More information on the anatomy of H&N is available on page 2




Age-standardised incidence and mortality, 2004-2023






- H&N cancer is **more common in males** than in females; male to female ratio of 2.4
- Risk of a H&N cancer **diagnosis in males is decreasing** with an average annual percentage change of **-1.1%**
- The average annual percentage change of the risk of a H&N cancer **diagnosis in females is +1.0%**

Age-standardised incidence trends



Incidence by main sub-location, 2014-2023






- **5-year net survival has been improving** for males and females in the last 20 years
- Diagnosis in **an early stage** is associated with a **better prognosis**
- More than **18,000 people** are living with the consequences of H&N cancer

Additional detailed information (including prevalence) can be found in the [Appendix of the Cancer Fact Sheet](#) and on the [website of the Belgian Cancer Registry](#)



5-year net survival, 2019-2023, % (95% CI)		
Lip	91.0%	(80.7%; 102.6%)
Oral cavity	55.5%	(53.0%; 58.1%)
Oropharynx	53.9%	(51.6%; 56.2%)
Nasopharynx	71.3%	(64.7%; 78.7%)
Hypopharynx	34.4%	(31.0%; 38.3%)
Larynx	67.3%	(64.3%; 70.5%)
Nasal cavity and paranasal sinuses	64.1%	(59.2%; 69.5%)
Salivary glands	82.1%	(76.6%; 87.8%)





- **Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.
- **Cancer maps:** Cities with at least 150,000 inhabitants are directly represented on the map as circles with a diameter relative to the population size, and a colour shading indicating the actual calculated ESR2013 in that city. The 19 municipalities of the Brussels Capital Region (more than 1,000,000 inhabitants) are divided in three separate circles, based on socio-economic parameters. The socio-economic status is lowest in the westernmost circle and highest in the easternmost circle. Methodological information is available in 'Cancer burden in Belgium 2004-2017, Belgian Cancer Registry, Brussels, 2020'.
- **Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).
- **ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.
- **Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).
- The net survival estimation was based on the regional lifetables 2023, obtained from the Statbel.
- **Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.
- **95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.
- **HPV:** Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of some H&N cancers.
- **H&N cancer is divided in sub-locations according to ICD-10 codes:**
 - **Lip:** C00
 - **Oral cavity:** C02-C05.0; C06
 - **Oropharynx:** C01; C05.1-C05.9; C09-C10
 - **Nasopharynx:** C11
 - **Hypopharynx:** C12-C13
 - **Larynx:** C32
 - **Nasal cavity and paranasal sinuses:** C30-C31
 - **Salivary glands:** C07-C08
 - **Other and ill-defined sites:** C14

**Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.*

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025